-
公开(公告)号：US20180134712A1
公开(公告)日：2018-05-17
申请号：US15574411
申请日：2016-05-24
申请人： Dong-Ming SHEN , Michael P. DWYER , Christopher J. SINZ , Deping WANG , Shawn J. STACHEL , Daniel V. PAONE , Ashley FORSTER , Richard BERGER , William D. SHIPE , Yili CHEN , Yimin QIAN , Shimin XU , Chunmei HU , Jianmin FU , Zhigang GUO , Haitang LI , Yingjian BO , Merck Sharp & Dohme Corp. , MSD R & D (China) Co., LTD.
发明人： Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yilli Chen , Yimin Qian , Shimin Xu , Chunmel Hu , William D. Shipe , Jianmin Fu , Zhigang Guo , HAITANG LI , Yingjian Bo
CPC分类号： C07D487/04 , A61K31/519 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28
摘要： The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
-
公开(公告)号：US10357481B2
公开(公告)日：2019-07-23
申请号：US15579878
申请日：2016-06-27
申请人： MERCK SHARP & DOHME CORP. , Gregori J. Morriello , Lehua Chang , Ashley Forster , Yili Chen , Michael P. Dwyer , Zack Zhiqiang Guo , Ming Wang , Shimin Xu , Yingjian Bo , Jianmin Fu
发明人： Gregori J. Morriello , Lehua Chang , Ashley Forster , Yili Chen , Michael P. Dwyer , Zack Zhiqiang Guo , Ming Wang , Shimin Xu , Yingjian Bo , Jianmin Fu
IPC分类号： A61K31/4196 , C07D471/04 , C07D487/04 , A61P25/28 , A61P25/22 , A61P25/18 , A61P25/16 , A61P25/06 , A61K31/52
摘要： The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：US20180162874A1
公开(公告)日：2018-06-14
申请号：US15579115
申请日：2016-06-20
申请人： Gregori J. MORRIELLO , Lehua CHANG , Ashley FORSTER , Yili CHEN , Michael P. DWYER , Richard BERGER , Ming WANG , Kausik K. NADA , Jaime L. BUNDA , William D. SHIPE , Merck Sharp & Dohme Corp.
发明人： Gregori J. Morriello , Michael P. Dwyer , Lehua Chang , Yili Chen , Ming Wang , Ashley Forster , Richard Berger , Kausik k Nanda , Jaime L Bunda , William D Shipe
IPC分类号： C07D498/04 , C07D473/34 , A61P25/18 , A61P25/16 , A61P25/28
CPC分类号： C07D498/04 , A61P25/06 , A61P25/16 , A61P25/18 , A61P25/28 , C07D473/34 , C07D487/04
摘要： The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：US10647727B2
公开(公告)日：2020-05-12
申请号：US15579115
申请日：2016-06-20
申请人： Merck Sharp & Dohme Corp. , Gregori J. Morriello , Michael P. Dwyer , Lehua Chang , Yili Chen , Ming Wang , Ashley Forster , Richard Berger , Kausik K. Nanda , Jamie L. Bunda , William D. Shipe
发明人： Gregori J. Morriello , Lehua Chang , Ashley Forster , Richard Berger , Kausik K. Nanda , William D. Shipe
IPC分类号： C07D487/04 , C07D498/04 , C07D473/34 , A61P25/06 , A61P25/28 , A61P25/18 , A61P25/16
摘要： The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：US20220242847A1
公开(公告)日：2022-08-04
申请号：US17611448
申请日：2020-05-18
申请人： Antonella CONVERSO , Abdellatif EL MARROUNI , Ashley FORSTER , Jessica L. FRIE , David N. HUNTER , Cheng WANG , Deping WANG , Merck Sharp & Dohme Corp.
发明人： Antonella Converso , Abdellatif El Marrouni , Ashley Forster , Jessica L. Frie , David N. Hunter , Cheng Wang , Deping Wang
IPC分类号： C07D401/06 , C07D401/14 , A61K45/06 , A61K31/506 , A61P31/18
摘要： The present disclosure is directed to pyridinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
-
公开(公告)号：US10174037B2
公开(公告)日：2019-01-08
申请号：US15576351
申请日：2016-05-31
发明人： Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yili Chen , Yimin Qian , Shimin Xu , Chunmei Hu
摘要： The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：US10160762B2
公开(公告)日：2018-12-25
申请号：US15574411
申请日：2016-05-24
发明人： Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yili Chen , Yimin Qian , Shimin Xu , Chunmei Hu , William D. Shipe , Jianmin Fu , Zhigang Guo , Haitang Li , Yingjian Bo
IPC分类号： C07D487/04 , A61K31/519 , A61P25/14 , A61P25/28 , A61P25/18 , A61P25/00 , A61P25/16
摘要： The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
-
公开(公告)号：US20180148453A1
公开(公告)日：2018-05-31
申请号：US15576351
申请日：2016-05-31
发明人： Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yili Chen , Yimin Qian , Shimin Xu , Chunmei Hu
摘要： The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：US20220064147A1
公开(公告)日：2022-03-03
申请号：US17413882
申请日：2019-12-13
发明人： Antonella Converso , Abdellatif El Marrouni , Ashley Forster , Jessica L. Frie , David N. Hunter , Scott D. Kuduk , Helen J. Mitchell , Philippe Nantermet , Deyou Sha , William Daniel Shipe , Cheng Wang , Deping Wang
IPC分类号： C07D403/06 , A61K45/06
摘要： The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
-
公开(公告)号：US20220062284A1
公开(公告)日：2022-03-03
申请号：US17411341
申请日：2021-08-25
发明人： Antonella Converso , Abdellatif El Marrouni , Anthony W. Shaw , David N. Hunter , Ashley Forster , Cheng Wang , Yunlong Zhang
IPC分类号： A61K31/513 , A61K45/06 , C07D403/06 , C07D401/06 , A61P31/18
摘要： The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.068 秒)
